CD133 expression (score 4–12) stratified by ND-SP size
| Polyp type and SCRC status | ND-SP n | NP-SP <5 mm Proportion CD133 n (%) | NP-SP ≥5 mm Proportion CD133 n (%) | p Value* |
|---|---|---|---|---|
| SSA/P/L (IS) | 37† | 1 (20) | 22 (69) | 0.057 |
| BSSA/P/L (IS) | 27 | 2 (40) | 8 (36) | 1 |
| HP (IS) | 20 | 0 | 1 (50) | 0.105 |
| All ND-SP (IS) | 87 | 3 (11) | 31 (55) | <0.001 |
| SSA/P/L-SCRC | 24 | 0 | 16 (76) | 0.027 |
| SSA/P/L | 13† | 1 (50) | 6 (54) | 1 |
| BSSA/P/L-SCRC | 17 | 2 (100) | 6 (40) | 0.205 |
| BSSA/P/L | 10 | 0 | 2 (29) | 1 |
| HP-SCRC | 11 | 0 | 1 (50) | 0.181 |
| HP | 9† | 0 | 0 | 1 |
*p Values from Fisher's exact test, indicating association between individuals polyps by size.
†Data on size not available for all polyps.
BSSA/P/L, borderline sessile serrated adenoma/polyp/lesion; HP, hyperplastic polyp; IS, ignoring SCRC status; ND-SP, non-dysplastic serrated polyp; SCRC, synchronous colorectal cancer; SSA/P/L, sessile serrated adenoma/polyp/lesion.